UK industry welcomes early access scheme, but says funding gap could limit interest
This article was originally published in Scrip
Executive Summary
The UK's long-awaited early access to medicines scheme (EAMS) is to be launched in April along with a new "promising innovative medicine" (PIM) designation that the government says will both give patients timely access to new drugs for serious diseases before they are approved and help companies secure investment for drugs under development at an earlier stage in the process.